Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection

Antiviral Research

Volumn 63, Issue 2, 2004, Pages 123-131

  Asmuth, David M ^a   Busch, Michael P ^b,c   Laycock, Megan E ^b,c   Mohr, Beth A ^d   Kalish, Leslie A ^d   Van Der Horst, Charles M ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Blood Centers of the Pacific   (United States)

^c Blood Systems Incorporated   (United States)

^d NEW ENGLAND RESEARCH INSTITUTES   (United States)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Hepatitis B; Hepatitis C; Human immunodeficiency virus; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; SURVIVAL RATE; VIRUS LOAD; VIRUS REPLICATION;

ADULT; ALANINE TRANSAMINASE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER; MALE; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; VIREMIA;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 4043106332     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.03.006     Document Type: Article

References (48)

1. Asmuth D.M., Kalish L.A., Laycock M.E., Murphy E.L., Mohr B.A., Lee T.-H., Gallarda J., Giachetti C., Dollard S.C., van der Horst C.M., Grant R.M., Busch M.P. Hepatitis B and C virus, human T-cell leukemia virus I/II, and human herpes virus-8 activation following allogeneic red blood cell transfusion in patients with advanced HIV-1 infection. Transfusion. 43:2003;451-458
2. Battegay M. Immunity to hepatitis C virus: a further piece of the puzzle. Hepatology. 24:1996;961-963
3. Bodsworth N.J., Cooper D.A., Donovan B. The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. J. Infect. Dis. 163:1991;1138-1140
4. Bonacini M., Puoti M. Hepatitis C in patients with human immunodeficiency virus infection: diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues. Arch. Intern. Med. 160:2000;3365-3373
5. Busch M.P., Collier A., Gernsheimer T., Carrington J.D., Flanigan T.P., Kashkari M., Kennedy M., Kumar P.N., Lane T.A., Mellors J.W., Mohandas K., Pollard R.B., Viele M., Yomtovian R., Holland P.V., McCurdy P.R. The Viral Activation Transfusion Study (VATS): rationale, objectives, and design overview. Transfusion. 36:1996;854-859
6. Chung R.T., Evans S.R., Yang Y., Theodore D., Valdez H., Clark R., Shikuma C., Nevin T., Sherman K.E. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 16:2002;1915-1923
7. Collier A.C., Kalish L.A., Busch M.P., Gernsheimer T., Assmann S.F., Lane T.A., Asmuth D.M., Lederman M.M., Murphy E.L., Kumar P., Kelley M., Flanigan T.P., McMahon D.K., Sacks H.S., Kennedy M.S., Holland P.V. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: the Viral Activation Transfusion Study: a randomized controlled trial. JAMA. 285:2001;1592-1601
8. Cribier B., Rey D., Uhl G., Schmitt C., Libbrecht E., Vetter D., Lang J.M., Kirn A., Stoll-Keller F. Quantification of hepatitis C virus RNA in peripheral blood mononuclear cells: a comparison between patients chronically infected by HCV and patients coinfected by HIV. Res. Virol. 147:1996a;325-332
9. Cribier B., Schmitt C., Rey D., Lang J.M., Kirn A., Stoll-Keller F. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res. Virol. 147:1996b;263-266
10. Daar E.S., Lynn H., Donfield S., Gomperts E., Hilgartner M.W., Hoots W.K., Chernoff D., Arkin S., Wong W.Y., Winkler C.A. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J. Acquir. Immune Defic. Syndr. 26:2001;466-472
11. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., Jurriaans S., Weel J., van Leeuwen R., Pakker N.G., Reiss P., Danner S.A., Weverling G.J., Lange J.M. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 14:2000;2895-2902
12. Dore G.J., Cooper D.A. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr. Opin. Infect. Dis. 14:2001;749-755
13. Eyster M.E., Fried M.W., Di Bisceglie A.M., Goedert J.J. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood. 84:1994;1020-1023
14. Fialaire P., Payan C., Vitour D., Chennebault J.M., Loison J., Pichard E., Lunel F. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection. J. Infect. Dis. 180:1999;574-575
15. Gilson R.J., Hawkins A.E., Beecham M.R., Ross E., Waite J., Briggs M., McNally T., Kelly G.E., Tedder R.S., Weller I.V. Interactions between HIV and hepatitis B virus in homosexual men: effects on the natural history of infection. AIDS. 11:1997;597-606
16. Greub G., Ledergerber B., Battegay M., Grob P., Perrin L., Furrer H., Burgisser P., Erb P., Boggian K., Piffaretti J.C., Hirschel B., Janin P., Francioli P., Flepp M., Telenti A. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 356:2000;1800-1805
17. Kelleher A.D., Al Harthi L., Landay A.L. Immunological effects of antiretroviral and immune therapies for HIV. AIDS. 11(Suppl. 1):1997;S149-S155
18. Koblin B.A., Taylor P.E., Rubinstein P., Stevens C.E. Effect of duration of hepatitis B virus infection on the association between human immunodeficiency virus type-1 and hepatitis B viral replication. Hepatology. 15:1992;590-592
19. Laskus T., Radkowski M., Piasek A., Nowicki M., Horban A., Cianciara J., Rakela J. Hepatitis C virus in lymphoid cells of patients coinfected with human immunodeficiency virus type 1: Evidence of active replication in monocytes/macrophages and lymphocytes. J. Infect. Dis. 181:2000;442-448
20. Macias J., Melguizo I., Fernandez-Rivera F.J., Garcia-Garcia A., Mira J.A., Ramos A.J., Rivera J.M., Pineda J.A. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 21:2002;775-781
21. Manegold C., Hannoun C., Wywiol A., Dietrich M., Polywka S., Chiwakata C.B., Gunther S. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin. Infect. Dis. 32:2001;144-148
22. Martinez E.H. Hepatitis B and hepatitis C co-infection in patients with HIV. Rev. Med. Virol. 11:2001;253-270
23. Mildvan D., Machado S.G., Wilets I., Grossberg S.E. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex. Lancet. 339:1992;453-456
24. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., Kumar P.N., Mintz L., Wallach F.R., Nemo G.J. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann. Intern. Med. 135:2001;17-26
25. Perez-Olmeda M., Garcia-Samaniego J., Soriano V. Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. AIDS. 14:2000;212
26. Perrillo R.P., Regenstein F.G., Roodman S.T. Chronic hepatitis B in asymptomatic homosexual men with antibody to the human immunodeficiency virus. Ann. Intern. Med. 105:1986;382-383
27. Pirisi M., Fabris C., Toniutto P., Falleti E., Tisminetzky S.G., Gerotto M., Soardo G., Vitulli D., Del Forno M., Baralle F., Bartoli E. Endogenous interferon-alpha concentration and outcome of interferon treatment in patients with chronic hepatitis C. Dig. Dis. Sci. 42:1997;767-771
28. Poles M.A., Dieterich D.T. Infections of the liver in HIV-infected patients. Infect. Dis. Clin. North Am. 14:2000;741-759
29. Puoti M., Bonacini M., Spinetti A., Putzolu V., Govindarajan S., Zaltron S., Favret M., Callea F., Gargiulo F., Donato F., Carosi G. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J. Infect. Dis. 183:2001;134-137
30. Puoti M., Gargiulo F., Roldan E.Q., Chiodera A., Palvarini L., Spinetti A., Zaltron S., Putzolu V., Zanini B., Favilli F., Turano A., Carosi G. Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment. J. Infect. Dis. 181:2000a;2033-2036
31. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., Quiros-Roldan E., Zanini B., Casari S., Carosi G. Mortality for liver disease in patients with HIV infection: a cohort study. J. Acquir. Immune Defic. Syndr. 24:2000b;211-217
32. Ragni M.V., Bontempo F.A. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J. Infect. Dis. 180:1999;2027-2029
33. Rockstroh J.K., Spengler U., Sudhop T., Ewig S., Theisen A., Hammerstein U., Bierhoff E., Fischer H.P., Oldenburg J., Brackmann H.H., Sauerbruch T. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am. J. Gastroenterol. 91:1996;2563-2568
34. Rockstroh J.K., Theisen A., Kaiser R., Spengler U., Sauerbruch T. Antiviral combination therapy decreases HIV-load but does not alter hepatitis C virus (HCV)-replication [abstract 735]. Hepatology. 26:1997;735
35. Rodriguez-Mendez M.L., Gonzalez-Quintela A., Aguilera A., Barrio E. Prevalence, patterns, and course of past hepatitis B virus infection in intravenous drug users with HIV-1 infection. Am. J. Gastroenterol. 95:2000;1316-1322
36. Rosenberg P.M. Hepatitis C: a hepatologist's approach to an infectious disease. Clin. Infect. Dis. 33:2001;1728-1732
37. Rutschmann O.T., Negro F., Hirschel B., Hadengue A., Anwar D., Perrin L.H. Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. J. Infect. Dis. 177:1998;783-785
38. Shelburne S.A. III, Hamill R.J., Rodriguez-Barradas M.C., Greenberg S.B., Atmar R.L., Musher D.W., Gathe J.C. Jr., Visnegarwala F., Trautner B.W. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 81:2002;213-227
39. Sulkowski M.S., Mast E.E., Seeff L.B., Thomas D.L. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 30(Suppl. 1):2000a;S77-S84
40. Sulkowski M.S., Moore R.D., Mehta S.H., Chaisson R.E., Thomas D.L. Hepatitis C and progression of HIV disease. JAMA. 288:2002a;199-206
41. Sulkowski M.S., Thomas D.L., Chaisson R.E., Moore R.D. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 283:2000b;74-80
42. Sulkowski M.S., Thomas D.L., Mehta S.H., Chaisson R.E., Moore R.D. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology. 35:2002b;182-189
43. Tedaldi E.M., Baker R.K., Moorman A.C., Alzola C.F., Furhrer J., McCabe R.E., Wood K.C., Holmberg S.D. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 36:2003a;363-367
44. Tedaldi E.M., Hullsiek K.H., Malvestutto C.D., Arduino R.C., Fisher E.J., Gaglio P.J., Jenny-Avital E.R., McGowan J.P., Perez G. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin. Infect. Dis. 36:2003b;1313-1317
45. Valdez H., Anthony D., Farukhi F., Patki A., Salkowitz J., Heeger P., Peterson D.L., Post A.B., Asaad R., Lederman M.M. Immune responses to hepatitis C and non-hepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS. 14:2000;2239-2246
46. Wit F.W., Weverling G.J., Weel J., Jurriaans S., Lange J.M. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. 186:2002;23-31
47. Yokozaki S., Takamatsu J., Nakano I., Katano Y., Toyoda H., Hayashi K., Hayakawa T., Fukuda Y. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy. Blood. 96:2000;4293-4299
48. Zylberberg H., Chaix M.L., Rabian C., Rouzioux C., Aulong B., Brechot C., Viard J.P., Pol S. Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects. Clin. Infect. Dis. 26:1998;1104-1106